AVROBIO (NASDAQ:AVRO – Get Rating) issued its quarterly earnings results on Tuesday. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.10), MarketWatch Earnings reports.
Shares of AVROBIO stock traded down $0.03 during trading on Wednesday, hitting $0.80. 9,979 shares of the stock were exchanged, compared to its average volume of 727,977. The stock has a market capitalization of $34.96 million, a price-to-earnings ratio of -0.28 and a beta of 1.73. The company has a fifty day moving average price of $1.23 and a 200-day moving average price of $2.57. AVROBIO has a 1-year low of $0.78 and a 1-year high of $11.00. The company has a current ratio of 10.27, a quick ratio of 10.27 and a debt-to-equity ratio of 0.09.
AVRO has been the topic of several recent research reports. Wedbush lowered their price target on shares of AVROBIO from $14.00 to $4.00 in a research note on Wednesday. Barclays lowered their price target on shares of AVROBIO from $6.00 to $4.00 in a research note on Wednesday. Finally, Zacks Investment Research upgraded shares of AVROBIO from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a research note on Monday, March 21st. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $6.86.
About AVROBIO (Get Rating)
AVROBIO, Inc, a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease.
- Get a free copy of the StockNews.com research report on AVROBIO (AVRO)
- Wendy’s Growth Story Has Come To An End
- Beyond Meat Could Sizzle After Q1 Results Are Released
- Can Six Flags(SIX) or Cedar Fair (FUN) Give Investors a Thrill Later This Year?
- Inflation Hasn’t Peaked At Reynolds Consumer Products
- Is Now The Time To Buy Coinbase (NASDAQ: COIN)?
Receive News & Ratings for AVROBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVROBIO and related companies with MarketBeat.com's FREE daily email newsletter.